Foundation Medicine

Foundation Medicine, Flatiron Health collaborate to develop data platform

Wednesday, December 3, 2014 01:03 PM

Foundation Medicine, a molecular information company based in Cambridge, Mass., and Flatiron Health, a healthcare technology company headquartered in New York, have announced a strategic collaboration to develop a unique, proprietary cloud-based information platform combining genomic and clinical treatment and outcomes data to significantly advance the field of precision medicine for cancer.

More... »


Cancer Innovation forum calls for improving cancer research ecosystem

Monday, October 27, 2014 12:58 PM

Accelerating the delivery of promising new cancer treatments depends on one critical requirement—ensuring patients are actively involved in the cancer research and drug development process from beginning to end.

More... »


MD Anderson, Foundation Medicine partner

Friday, August 15, 2014 02:52 PM

The University of TexasMD Anderson Cancer Center has announced an alliance with Cambridge, Mass.-based Foundation Medicine. The teams are opening a randomized, controlled trial to determine whether targeted therapies selected based on tumor molecular profiling compared with treatment not selected on this basis results in longer progression-free survival in patients with advanced disease.

More... »

Amgen joins NCI to accelerate development of personalized cancer treatments

Tuesday, June 17, 2014 10:26 AM

Amgen will collaborate with the National Cancer Institute (NCI), part of the NIH, and other public and private sector partners, on the Lung Master Protocol (Lung-MAP), a new clinical trial program that will use biomarker-driven research and genomic profiling to match squamous cell lung cancer patients to investigational treatments based on their individual cancer profiles. Lung-MAP is the first trial of its kind to study a large number of rare lung cancer subsets under one trial protocol.

More... »

U.S. cancer researchers launching five-drug personalized medicines trial

Monday, April 21, 2014 01:12 PM

U.S. cancer researchers plan to launch a five-drug clinical trial for patients with advanced lung cancer in mid-May, in a public-private collaboration between several major cancer organizations and five pharmaceutical companies that marks the second American multi-drug research program into personalized medicines to treat different cancers.

More... »

Foundation Medicine, Agios collaborate on cancer metabolism programs

Friday, April 5, 2013 11:36 AM

Foundation Medicine, a molecular information company, and Agios Pharmaceuticals, a biopharmaceutical company, have formed a multi-year diagnostic partnership for Agios' lead programs in cancer metabolism.

More... »

Foundation Medicine expands Series B financing to $56M

Wednesday, January 23, 2013 03:07 PM

Foundation Medicine, a Cambridge Mass.-based molecular information company, has expanded its Series B financing, raising an additional $13.5 million and bringing the total raised in the round to $56 million. The new investors include Bill Gates, Evan Jones and Yuri Milner.

More... »

Foundation Medicine, Ariad collaborate on genomic characterization in AP26113 oncology program

Wednesday, November 14, 2012 12:28 PM

Foundation Medicine, a molecular information company, and Ariad Pharmaceuticals, an emerging global oncology company, announced a genomic profiling collaboration to study AP26113, Ariad's investigational dual-inhibitor of ALK and EGFR in patients with non-small cell lung cancer (NSCLC) and other cancers.

More... »

Foundation Medicine, AstraZeneca collaborate on genomic profiling for targeted cancer therapies

Tuesday, November 13, 2012 09:23 AM

Foundation Medicine, a molecular information company based in Cambridge, Mass., has formed a multi-year collaboration with global biopharmaceutical company AstraZeneca to identify alterations found in cancer-related tumor genes that may predict a person's response or resistance to targeted medicines.

More... »

Foundation Medicine completes $42.5M Series B financing

Friday, September 21, 2012 12:18 PM

Foundation Medicine, a Cambridge, Mass.-based molecular information company focused on bringing comprehensive cancer genomic analysis to routine clinical care, has completed a $42.5 million Series B financing.

More... »

CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 15

Cancer Treatment Centers of America chooses WCG as its exclusive IRB, sheds five local hospital IRBs

Five southern research groups form public-private network to help save time, money for clients with early-stage biologics

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

December

Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs